SABBiotherapeutics reports third quarter 2021 financial results and provides company update
SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2021 and provided a company update
By Divya S
Published - Nov 22, 2021, 01:52 PM ET
Last Updated - Jul 04, 2024, 06:54 AM EDT
AdvancedSAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis
Awarded additional $60.5 million from DoD in expanded scope for advancement of SAB-185
Strengthened leadership team through appointment of Russell Beyer as Chief Financial Officer
SiouxFalls, S.D., November 22, 2021 – SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2021 and provided a company update.
